< Back to latest news & events

Event

Life Sciences Patent Network North America 2019 – San Francisco

October 2019

Event date: 16th October 2019

HGF Partner Iain Armstrong will be attending and speaking at LSPN North America 2019 on 16th October. The session will cover ‘CAR–T and other immunotherapies’.

Immunotherapies, such as CAR-T cells, are a hugely promising therapeutic area, both in terms of clinical benefits and potential market size. The treatments have proven remarkably effective in achieving positive outcomes in forms of cancer that are otherwise difficult to treat. As a result, their clinical use has recently been approved in both the US and Europe.

The potential for this market has already spurred tens of billion of dollars in acquisition activity by those wishing to enter the field, and investment in this area is continuing to grow. The expanding market means patenting is becoming more important.

Iain Armstrong will discuss the following:

  • Development and changes of patenting around immunotherapies such as CAR-T cells
  • Areas providing subject matter for new filing
  • The most common difficulties for patent applications and how they can be avoided.

He will also analyse the technical areas with the strongest patenting activity, which include:

  • The development of CARs targeting new forms of cancer
  • The production of CARs with new or improved biological activities
  • The generation of CARs with improved effectiveness in solid tumours
  • Improved methods of CAR-T cell production.

Latest updates

Avoiding Legal Pitfalls: The Notting Hill Bag Company's Costly Mistake

[2025] EWHC 1793 (IPEC) – Natasha Courtenay-Smith and Notting Hill Bag Company Limited v The Notting Hill Shopping Bag Company Limited, Nangialai Takanai, The Notting Hill Shopper Bag Ltd, Ehsanullah …

Read article
Event - 12th September 2025

Wolters Kluwer Breakfast Panel on AI & IP at AIPPI

Sofie McPherson, Patent Director at HGF, will be moderating a special breakfast panel session hosted by Wolters Kluwer at the AIPPI World Congress in Yokohama on 15 September 2025. Session …

Event details

T1465/23 – No Narrowing by Description—EPO Board Terminates Inventive Step Analysis for Arbitrary Modifications Citing G1/24 and G1/19

“The potential patentability of a specific narrow embodiment…cannot render a claim allowable which, due to its breadth, encompasses a multitude of other, non-inventive embodiments” – r. 3.5. Background EP3113515 was …

Read article

Wrestling with G1/24 – How should the claims be interpreted in view of the description?

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description. However, the decision was light on how, in …

Read article

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article